Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DBH | P09172 | 11/20 | 0.55 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3159524 | 0.70 | CHRNB2 (0.39) | DBHALDH1A1CYP1A2POLB | |
| SCHEMBL3174561 | 0.63 | — | — | |
| SCHEMBL1520865 | 0.58 | IDO1 (1.00) | IDO1 | |
| SCHEMBL4798547 | 0.58 | IDO1 (0.58) | DBHIDO1 | |
| SCHEMBL4798553 | 0.58 | IDO1 (0.58) | IDO1 | |
| SCHEMBL28274630 | 0.58 | IDO1 (0.58) | IDO1 | |
| Hydrochloric Acid SCHEMBL660379 | 0.56 | IDO1 (1.00) | IDO1 | |
| SCHEMBL5521938 | 0.56 | MEN1 (0.59) | IDO1ALDH1A1CYP1A2POLB | |
| SCHEMBL28768674 | 0.56 | IDO1 (0.48) | DBHIDO1 | |
| SCHEMBL31091006 | 0.55 | IDO1 (0.48) | IDO1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010049-A1 | Novel Tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-01-14 | — | — | US | claimed |
| US-20100010049-A1 | Novel Tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010049-A1 | Novel Tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof | TYR, MITF, MAOA | DBH 204/4885IDO1 45/4885ALDH1A1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.